Shingles Vaccination and Treatment Dosing
For herpes zoster vaccination in immunocompetent adults aged ≥50 years, administer recombinant zoster vaccine (RZV/Shingrix) as a 2-dose series given intramuscularly 2-6 months apart; for acute herpes zoster treatment, use oral antivirals within 72 hours of rash onset.
Vaccination Recommendations
Primary Recommendation for Prevention
RZV (Shingrix) is the preferred vaccine for all immunocompetent adults aged ≥50 years, administered as 2 doses (0.5 mL each) intramuscularly, separated by 2-6 months (minimum interval: 4 weeks) 1, 2. This recommendation is based on superior efficacy compared to the older live attenuated vaccine (ZVL/Zostavax).
Key Vaccination Details:
- Efficacy: RZV demonstrates 97.2% efficacy in preventing herpes zoster in adults aged ≥50 years, with 91.3% efficacy in those ≥70 years 3
- Duration of protection: Maintained above 83% for up to 8 years 3
- Prior zoster history: Vaccinate regardless of previous herpes zoster episodes 4, 1
- Previous ZVL vaccination: If previously received ZVL, administer RZV at least 2 months after ZVL 4
Age-Specific Guidance:
- Ages 50-59 years: 2-dose RZV series 1
- Ages ≥60 years: 2-dose RZV series preferred; ZVL (single dose) is an alternative but inferior option 4
- Ages ≥19 years who are immunocompromised: 2-dose RZV series 2
Important Vaccination Caveats:
- Pregnancy: Consider delaying RZV until after pregnancy; ZVL is contraindicated 4
- Severe immunocompromising conditions: ZVL is contraindicated; RZV can be administered 4, 2
- No serologic testing needed: Do not check varicella immunity before vaccination 5
- Timing with other vaccines: Can be administered concomitantly with other age-appropriate vaccines
Acute Herpes Zoster Treatment
Antiviral Dosing for Acute Infection
Initiate oral antiviral therapy within 72 hours of rash onset to maximize benefit in reducing acute pain severity, accelerating healing, and preventing postherpetic neuralgia 5.
Recommended Antiviral Regimens:
First-line options (choose one):
Valacyclovir: 1,000 mg (1 g) three times daily for 7 days 5
- Alternative: 1.5 g twice daily for 7 days (equally effective with improved compliance) 6
Famciclovir: 500 mg three times daily for 7 days 5
- Alternative dosing: 750 mg once daily, 500 mg twice daily, or 250 mg three times daily (all comparable efficacy) 7
Acyclovir: 800 mg five times daily for 7-10 days 8, 5
- Note: Less convenient dosing schedule; 800 mg five times daily is superior to 400 mg five times daily 8
Treatment Priorities:
The 72-hour window is critical - antiviral efficacy decreases significantly if treatment is delayed beyond this timeframe. Benefits include:
- Shortened viral shedding period
- Accelerated time to crusting and healing
- Reduced formation of new lesions
- Decreased severity and duration of acute pain
- Lower risk of postherpetic neuralgia 8, 5
Adjunctive Pain Management:
While antivirals are the cornerstone, consider supplementing with:
- Analgesics for acute pain control
- Corticosteroids in select patients (though evidence is mixed)
- Tricyclic antidepressants or other agents for established postherpetic neuralgia 5
Common Pitfalls to Avoid:
- Delaying treatment: Do not wait for laboratory confirmation; treat clinically suspected cases within 72 hours
- Underdosing acyclovir: The 800 mg five times daily dose is necessary; 400 mg five times daily is inadequate 8
- Confusing prevention with treatment: Zoster vaccine does not treat acute infection or prevent/treat postherpetic neuralgia 5
- Missing immunocompromised patients: These patients require prompt treatment and may benefit from vaccination with RZV (not ZVL) 2